Sonoma Pharmaceuticals (SNOA) Competitors $3.09 -0.07 (-2.22%) Closing price 04:00 PM EasternExtended Trading$2.92 -0.17 (-5.34%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. FNCH, SXTC, OVID, NAII, SLGL, BIVI, CGTX, CMMB, ASBP, and LGVNShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Finch Therapeutics Group (FNCH), China SXT Pharmaceuticals (SXTC), Ovid Therapeutics (OVID), Natural Alternatives International (NAII), Sol-Gel Technologies (SLGL), BioVie (BIVI), Cognition Therapeutics (CGTX), Chemomab Therapeutics (CMMB), Aspire Biopharma (ASBP), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Finch Therapeutics Group China SXT Pharmaceuticals Ovid Therapeutics Natural Alternatives International Sol-Gel Technologies BioVie Cognition Therapeutics Chemomab Therapeutics Aspire Biopharma Longeveron Finch Therapeutics Group (NASDAQ:FNCH) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Is FNCH or SNOA more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Sonoma Pharmaceuticals' return on equity of -68.98% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Sonoma Pharmaceuticals -26.82%-68.98%-26.39% Do insiders and institutionals hold more shares of FNCH or SNOA? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor FNCH or SNOA? Sonoma Pharmaceuticals received 206 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote. CompanyUnderperformOutperformFinch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Which has higher earnings and valuation, FNCH or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics Group$110K200.75-$74.75M-$8.82-1.56Sonoma Pharmaceuticals$13.97M0.36-$4.84M-$4.02-0.77 Does the media favor FNCH or SNOA? In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 0 mentions for Finch Therapeutics Group. Sonoma Pharmaceuticals' average media sentiment score of 0.94 beat Finch Therapeutics Group's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Finch Therapeutics Group Neutral Sonoma Pharmaceuticals Positive Which has more volatility and risk, FNCH or SNOA? Finch Therapeutics Group has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. SummarySonoma Pharmaceuticals beats Finch Therapeutics Group on 11 of the 15 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.99M$4.32B$5.56B$8.50BDividend YieldN/A42.67%5.28%4.17%P/E Ratio-0.7727.8226.6419.64Price / Sales0.3668.18407.99152.17Price / CashN/A51.0838.2534.64Price / Book1.035.746.974.60Net Income-$4.84M$66.95M$3.23B$248.06M7 Day Performance-6.93%-2.95%-0.98%-1.03%1 Month Performance0.65%14.68%7.70%3.50%1 Year Performance1,587.60%17.75%31.32%12.68% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.2398 of 5 stars$3.09-2.2%N/A+1,573.7%$4.99M$13.97M-0.77180Upcoming EarningsGap UpFNCHFinch Therapeutics Group0.3437 of 5 stars$13.60+0.7%N/A+861.2%$21.84M$110K-1.54190Gap UpSXTCChina SXT Pharmaceuticals0.3811 of 5 stars$1.32-5.0%N/A-77.4%$20.89M$1.82M0.0090Short Interest ↑Gap DownOVIDOvid Therapeutics4.3827 of 5 stars$0.29+6.5%$2.78+860.1%-91.0%$20.62M$548K-0.6260NAIINatural Alternatives International0.7714 of 5 stars$3.31-0.4%N/A-47.7%$20.43M$125.48M-2.56290News CoverageShort Interest ↑SLGLSol-Gel Technologies3.0091 of 5 stars$7.32+1.5%$40.00+446.7%-11.5%$20.38M$12.10M-21.5250Positive NewsShort Interest ↓BIVIBioVie2.4521 of 5 stars$1.07+2.9%$3.00+180.4%+142.1%$19.86MN/A-0.1110Positive NewsCGTXCognition Therapeutics3.6475 of 5 stars$0.32+32.6%$5.63+1,674.4%-87.1%$19.65MN/A-0.3320Short Interest ↓Gap UpHigh Trading VolumeCMMBChemomab Therapeutics3.5804 of 5 stars$1.35+2.3%$8.50+529.6%+11.4%$19.39MN/A-1.3520Positive NewsASBPAspire BiopharmaN/A$0.39-10.5%N/AN/A$19.07MN/A0.00N/ANews CoverageGap DownLGVNLongeveron3.5104 of 5 stars$1.25+0.8%$8.67+593.3%-27.1%$18.66M$2.23M-0.2020Gap Down Related Companies and Tools Related Companies Finch Therapeutics Group Competitors China SXT Pharmaceuticals Competitors Ovid Therapeutics Competitors Natural Alternatives International Competitors Sol-Gel Technologies Competitors BioVie Competitors Cognition Therapeutics Competitors Chemomab Therapeutics Competitors Aspire Biopharma Competitors Longeveron Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNOA Stock Free SNOA Stock Alerts